Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) – What Benchmark are We Aiming at in Continuing Medical Education (CME)?

Bernd Hagen and Reinhard Griebenow

*Department of Evaluation and Quality Assurance, Central Institute for Statutory Health Care in Germany, Cologne/Berlin, Germany; †Praxis Rheingalerie, Cologne, Academic Teaching Practice, University of Cologne, Cologne, Germany

**ABSTRACT**

Physicians always aim to improve their patients’ health. CME should be designed not only to provide knowledge transfer, but also to influence clinical decision-making and to close performance gaps. In a retrospective study we analysed prescription rates for APT in 254,932 CAD patients (male: 64.4%), treated in atotal of 3,405 practices in 2019 in aDMP in the region of North Rhine, Germany. Analyses were run for the whole study population stratified by sex as well as for subgroups of patients suffering from myocardial infarction/acute coronary syndrome, or who have been treated with percutaneous coronary intervention or bypass surgery. Patients mean age was 72.7 ± 11.2 years (mean ± 1SD), mean duration of DMP participation was 7.2 ± 4.7 years, and mean cumulative number of DMP visits was 27 ± 17. APT prescription rates were 85.0% in male and 78.8% in female CAD patients. In subgroups of male CAD patients APT prescription rates were between 89.7% and 92.8%, in the same subgroups of female CAD patients the corresponding rates were between 87.8% and 92.0%. Rates for amissing APT prescription per practice were between .0044% and .0062% for male and female CAD patients, respectively. Rates for amissing APT prescription per practice and DMP visit were .0002% for both sexes. These results suggest that a DMP can achieve high attainment rates for APT in CAD. To further improve attainment rates, consideration of absolute numbers of eligible patients per practice or physician is probably more appropriate than expression of performance as percentage values. This is especially true if attainment rates show substantial variations between subgroups, if subgroups show substantial variation in size, if attainment rates are already in the magnitude of 80% or higher, and if there are disparities in the evidence base underlying treatment recommendations related to subgroups.

**Introduction**

Physicians always aim to improve their patients’ health and consequently also improve community health. CME should always be designed to support this goal and thus not only provide knowledge transfer, but also influence clinical decision-making and fill performance gaps. This concept has been described as Moore’s pyramid [1].

However, in clinical practice, achieving changes in community health may not only depend on physician performance, but also on e.g. access of patients to health care, evidence based and acceptance of treatment recommendations, and availability of treatment. Thus, the relative weight of CME to achieve improvements in community health needs to be determined.

This retrospective study has analysed what CME would have to address to improve physician performance in patients with a widespread disease [2], inscribed into a DMP, which offers free access to all patients, and treated with APT, a well-established and universally available treatment option.

**Methods**

Background and design of DMPs in Germany has been described elsewhere [3].

In brief, the DMP CAD contains the following elements, which are mandatory:

- Recommendations for diagnosis and treatment of CAD
- Definition of benchmarks (“quality goal”) to be achieved (e.g. prescription rate for APT of ≥ 80%)
- Standardised electronic documentation of every patient visit

**CONTACT** Bernd Hagen bhagen@zi.de Central Institute for Statutory Health Care in Germany, Sedanstr. 10-16, 50668 Cologne, Germany

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
At least one mandatory visit in each quarter of the year.

Feedback reports to be issued every 6 months to the treating physician, which present core patient characteristics and treatment results for all patients enrolled by the individual physician as well as for all patients in the region of North Rhine.

We have analysed the prescription rates for APT in all patients enrolled in the DMP CAD in North Rhine on Dec. 31st, 2019, from the database of the Central Research Institute for Statutory Healthcare in Germany, which hosts all follow up data of DMP patients in the region of North Rhine.

In the DMP patients are grouped according to the following definitions:

1. Myocardial infarction: MI/acute coronary syndrome at any time, n = 107,028, 42% of all patients
2. Percutaneous coronary intervention (PCI): PCI at any time, n = 61,009, 23.9%
3. Bypass operation: Coronary artery bypass operation at any time, n = 21,709, 8.5%
4. Others: All patients not falling in groups 1–3., n = 113,847, 44.7%

Groups 1–3 are not mutually exclusive.

Numbers of patients without APT have also been related to:

1. the number of practices in the North Rhine region treating DMP CAD patients, n = 3,083–3,405
2. the number of DMP visits over the whole period of patients’ DMP participation, n = 22–39 (min-max)

Data analysis has been performed by use of IBM SPSS 19.0 statistics software.

Results

On Dec. 31st, 2019, 254,932 patients had been enrolled in the DMP CAD North Rhine, equalling an estimated coverage rate of about 72% of all patients with CAD in the North Rhine region (calculated from 2), further demographic data are shown in Table 1.

Median number of DMP CAD patients per practice was 59 (interquartile range, IQR, 29–100), 39 (IQR 20–66) for male and 20 (IQR 9–35) for female patients. Mean age of all patients was 72.7 ± 11.2 yrs., mean duration of DMP participation was 7.2 ± 4.7 yrs., and mean cumulative number of DMP visits over the whole duration of DMP participation was 26.9 ± 17.3. Percentage of male patients was 64.4%, 88.8% of all CAD patients suffered from arterial hypertension, and 47.7% from diabetes mellitus, respectively.

Mean age, mean duration of DMP participation, and mean number of DMP visits differed by patients’ subgroup. Compared to all other subgroups mean age was higher in patients with bypass surgery. In all three subgroups, percentage of male patients was larger compared to “others”, as well as participation was longer and there were more DMP visits.

A total of 3,405 practices have enrolled patients in the DMP, number of practices per subgroup are shown in Table 2.

Excluding patients with contraindications and/or indications for oral anticoagulation yielded 225,977 CAD patients eligible for APT.

Prescription rates for the entire group as well as for subgroups are shown in Table 2, further stratified for sex, number of practices, and number of patient contacts in the DMP (“DMP visit”).

85.0% of all male CAD patients were treated with APT, the corresponding percentage of female patients was 78.8%. Compared to “others” APT prescription rates were higher for male (89.7–92.8%) as well as for female CAD patients (87.8–92.0%) in all other three subgroups. APT was missing in 15.0% of male and 21.2% of female CAD patients, with a substantially higher percentage of missing APT in the “others” group compared to all other three subgroups (male: 7.2–10.3%, female: 8.0–12.2%).

| Table 1. Baseline demographic data. | All patients | Myocardial infarction | PCI | Bypass surgery | Others |
|------------------------------------|--------------|------------------------|-----|----------------|--------|
|                                    | Mean or n    | ± 1 SD or %            | Mean or n    | ± 1 SD or % | Mean or n    | ± 1 SD or % | Mean or n    | ± 1 SD or % | Mean or n    | ± 1 SD or % |
| Age (yrs)                          | 72.7 ± 11.2  | 72.3 ± 11.4            | 72.4 ± 11.1  | 75.8 ± 9.7  | 72.7 ± 11.2  | 72.3 ± 11.4  | 75.8 ± 9.7  | 72.7 ± 11.2  |
| Male sex                           | 164,197      | 64.4 ± 3.3             | 69.1 ± 4.3   | 70.5 ± 5.5  | 78.2 ± 4.8   | 16,968       | 66,111      | 58.4         |
| DMP (yrs)                          | 7.2 ± 4.7    | 8.3 ± 5.5              | 8.3 ± 5.5    | 10.6 ± 4.8  | 5.7 ± 2.1    | 7.2 ± 4.7    | 8.3 ± 5.5    | 10.6 ± 4.8  |
| N of DMP visits                    | 26.9 ± 17.3  | 31.0 ± 16.6            | 20.5 ± 13.9  | 18.3 ± 5.5  | 21.7 ± 15.5  | 26.9 ± 17.3  | 31.0 ± 16.6  | 20.5 ± 13.9  |
| Arterial hypertension              | 226,492      | 88.8 ± 9.7             | 90.8 ± 5.6   | 91.2 ± 4.0  | 94.0 ± 5.5   | 20,404       | 98,082      | 86.2         |
| Diabetes mellitus                  | 121,502      | 47.7 ± 4.8             | 52.1 ± 4.8   | 46.7 ± 3.0  | 53.0 ± 4.7   | 52,127       | 53,656      | 47.1         |
If related to the number of practices, APT was missing in .0044% of male and .0062% of female CAD patients per practice (.0022–.0039% for subgroups), and if related to the number of practices and number of DMP visits, APT was missing in .0002% of male as well as female CAD patients (.0001% for subgroups).

Discussion

Following an index event (e.g. myocardial infarction) with hospital admission, prescription rates for APT, as part of a secondary preventive strategy, are usually high [4–10], but do not reach 100%. Age, female sex, race, polypharmacy due to comorbidities, and coding problems (among others) are variables which have been shown to have a negative impact on prescription rates at hospital discharge [11–17].

All the aforementioned variables also negatively influence long-term adherence, which has further been shown to decline due to poor health literacy, cognitive or psychic impairment, and medication cost issues (among others) [18–21]. Long-term adherence to APT has been reported to decline substantially over time [17,22,23], but more favourable results have also been reported [5,6,10,12,24–28].

Though we have no data regarding patient adherence, overall prescription rates for APT nevertheless document that participating physicians show a persistently high motivation for secondary prevention in this group of patients with a long-term history of CAD.

Absolute numbers of patients in the range of 17,000 to 22,000 (depending on sex) not being prescribed APT may nevertheless raise concern.

However, further analysis of subgroups shows that attainment rates for APT in subgroups exhibit substantial variation: thus, APT has been prescribed in about 92% of patients who have undergone a PCI and in nearly 90% of all patients who have suffered from myocardial infarction or undergone a coronary bypass operation, respectively.

It is only in the “others” group that between 23 and 30% (depending on sex) of the patients do not get APT. However, inclusion into the DMP does not require validation of the diagnosis by additional anatomical and/or functional tests, but could be based on clinical symptoms only. Thus, this group may well contain patients who by definition fall under “primary prevention”, for which the prognostically favourable effect of APT is still less clear than in secondary prevention [29,30]. Evidence for similarly mixed patient groups is scarce and clinical trials have also not been able to unequivocally show a positive effect of APT in these patients [31,32].

Thus, our study demonstrates that use of overall attainment rates to guide needs assessment, definition of learning objectives, and ultimately benchmarks in CME is less appropriate, if

- prescription rates show substantial variations between subgroups,
- attainment rates are already in the order of magnitude of 80% or higher, and
- there are disparities in the evidence base underlying treatment recommendations related to subgroups.

Furthermore, if taking into consideration that CME should provide physicians with information as closely related to their particular working environment as possible to facilitate implementation, benchmarks to be propagated by CME become even more challenging:

- While percent values signal undertreatment of women (78.8% vs. 85% in male patients), this looks different from the perspective of the individual physician: absolute numbers break down to 6.4 male vs. 5 female patients without APT per practice.
- According to the Federal Association of Statutory Health Insurance Physicians in Germany (www.kbv.de/html/zahlen.php), in 2019, approximately 553 m cases have been treated in 101,932 practices, equalling an average number of 1,356
patient cases per practice. Assuming a 50%-distribution between sexes (i.e. 678 cases each), it turns out that to further raise prescription rates for APT (towards 100%) in the “PCI” group it would need to identify 1 male patient in every practice and 1 female patient in every 3rd practice, respectively, or to put it in other words, 1 male patient in 678 male patients per quarter, and 1 female patient in 2,034 female patients per quarter. Likewise, to further raise prescription rates for APT in the “myocardial infarction” group it would need to roughly identify 1 female patient in every practice (1/678) and 2 male patients per practice (1/339), respectively. But to achieve the same result in the much smaller “bypass operation” group, it would need to identify 1 male patient in every 2nd practice (1/1,356) and 1 female patient in every 6th practice (1/4,068), respectively.

These figures demonstrate that

- use of just percentage values as performance measure may be misleading, especially when subgroups show substantial variation in size,
- differences, which may appear significant, if looking into larger patient cohorts (e.g. on the regional or national level), may turn out to be marginal in relation to how often these patients can be found in the patient cohort treated by an individual family physician. Whether CME may play a role in improving identification of these few patients needs to be determined. However, data from a scenario with a large need for change (i.e. the US opioid crisis) show that CME has been rated as being of minor importance to drive change [33]. On the other hand, theoretically useful interventions, which are related to the status of the individual patient, such as the use of clinical decision aids and/or alerts in electronic health records or on patients’ mobile phones so far have shown variable and partly disappointing results [34–40].

Limitations:
Our study has several limitations:

a. Since our study population represents only about 72% of all patients with CAD in the region of North Rhine this might have had a confounding effect as well as potential differences in inclusion rates in North Rhine subregions [41].

b. Number of APT naive patients per total quarterly number of patients per practice refers to nationwide numbers of practices of all specialities and may not reflect the numbers in the practices participating in the DMP CAD North Rhine.

c. For calculation of number of quarterly patients per practice we have assumed a 50:50 distribution of physician-patient contacts between sexes, without any adjustment for age, and comorbidities, since more detailed data are not publicly available. We though believe that our data give a realistic estimate of the order of magnitude of the issue.

d. Furthermore, these results may have been influenced by documentation disparities, which have been demonstrated to occur in a significant number of patients in similar studies [9,42–49].

e. We have no data to estimate to which extent complications emerging in the course of treatment might have influenced the results of this study, though e.g. bleeding complications might have occurred in a non-negligible proportion of patients [50–52].

We though speculate that the latter two (c/d) might have had an influence on the results, since otherwise an average number of 27 DMP visits representing the number of missed opportunities to prescribe APT would be hardly plausible.

In conclusion, our study demonstrates that

- a multifaceted intervention, like a DMP, can achieve high attainment rates for APT in CAD
- to describe the benchmark for CME to further improve attainment rates, consideration of absolute numbers of eligible patients per physician is probably more appropriate than expression of performance as percentage values in particular if
  o attainment rates show substantial variations between subgroups,
  o subgroups show substantial variation in size,
  o attainment rates are already in the magnitude of 80% or higher, and
  o there are disparities in the evidence base underlying treatment recommendations related to subgroups.

These results also indicate that defining the need for change (i.e. outcome of needs assessment) not only along percentage values, but as number of eligible patients per physician and/or practice may yield a more personalised and hence more motivating approach for participants in CME.
Disclosure Statement

No potential conflict of interest was reported by the authors.

References

[1] Moore DE, Green JS, Gallis HA. Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities. JCEHP. 2009;29:1–15.
[2] Busch MA, Kuhnert R. 12-Month prevalence of coronary heart disease in Germany. J Health Monit. 2017;2(1):58–63.
[3] Hagen B, Griebenow R, Altenhofen L, et al. Time course of change in prescription behaviour after targeted continuing medical education in a closed loop system of repeated standardized documentation and feedback. J Eur CME. 2014;3:24697.
[4] Bebb O, Hall M, Fox KAA, et al. Performance of hospitals according to the ESC ACCA quality indicators and 30-day mortality for acute myocardial infarction: national cohort study using the UK Myocardial Ischemia National Audit Project (MINAP) register. Eur Heart J. 2017;38:974–982.
[5] Bruggmann C, Iglesias JF, Gex-Fabry M, et al. Long-term quality of prescription for ST-Segment-Elevation Myocardial Infarction (STEMI) patients: a real world 1-year follow-up study. Am J Cardiovasc Drugs. 2020;20:105–115.
[6] Czarny MJ, Nathan AS, Yeh RW, et al. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol. 2014;37(8):505–513.
[7] Engel J, Damen NL, van der Wulp I, et al. Adherence to cardiovascular practice guidelines in the management of non-ST-elevation acute coronary syndromes: a systematic literature review. Curr Cardiol Rev. 2017;13:3–27.
[8] Ardoiino I, Rossio R, Di Blanca D, et al. Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people. Br J Clin Pharmacol. 2017;83:2528–2540.
[9] Hall M, Bebb O, Dondo TB, et al. Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. Eur Heart J. 2018;39:3798–3806.
[10] Wang R, Neuenschwander FC, Filho AL, et al. Use of evidence-based interventions in acute coronary syndrome- subanalysis of the ACCENT registry. Arq Bras Cardiol. 2014;102(4):319–326.
[11] Auer R, Gencer B, Raber L, et al. Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medications. PLoS One. 2014;9(3):e93147.
[12] Bhagwat MM, Woods JA, Dronovalli M, et al. Evidence-based intervention in primary care following acute coronary syndrome in Australia and New Zealand: a systematic scoping review. BMC Cardiovasc Disord. 2016;16:214–228.
[13] Davis AM, Vinci LM, Okwuosa TM, et al. Cardiovascular health disparities: a systematic review of health care interventions. Med Care Res Rev. 2007;64(Suppl.):295–1008.
[14] Lee JH, Bae MH, Yang DH, et al. Contemporary trends of optimal evidence-based medical therapy at discharge for patients surviving acute myocardial infarction from the korea acute myocardial infarction registry. Clin Cardiol. 2015;38(6):350–356.
[15] Opotowsky AR, McWilliams JM, Cannon CP. Gender differences in aspirin use among adults with coronary heart disease in the USA. Soc Gen Intern Med. 2007;22:55–61.
[16] Redfern J, Hyun K, Chew DP, et al. Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand. Heart. 2014;100:1281–1288.
[17] Roth GA, Gillespie CW, Mokdad AA, et al. Aspirin use and knowledge in the community: a population- and health facility based survey for measuring local health system performance. BMC Cardiovasc Disord. 2014;14:16–22.
[18] Kronish IM, Ye S. Adherence to cardiovascular medications: lessons learned and future directions. Prog Cardiovasc Dis. 2013;55(6):590–600.
[19] Maddox TM, Chan PS, Sperutz JA, et al. Variation in CAD secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR®. J Am Coll Cardiol. 2014;63(6):539–546.
[20] Makam RCP, Erskine N, McManus DD, et al. Decade long trends (2001-2011) in the use of evidence-based medical therapies at the time of hospital discharge for patients surviving acute myocardial infarction. Am J Cardiol. 2016;118(12):1792–1797.
[21] Redmond P, McDowell R, Grimes TC, et al. Unintended discontinuation of medication following hospitalization: a retrospective cohort study. BMJ Open. 2019;9(6):e024747.
[22] Mangiapane S, Busse R. Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction. Dtsch Arztebl Int. 2011;108(450):856–862.
[23] Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882–887.
[24] Carballo D, Rodondi N, Auer R, et al. Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. PLoS One. 2019;14(2):e0211464.
[25] Gu Q, Dillon CF, Eberhardt MS, et al. Preventive aspirin and other antiplatelet medication use among U.S. adults aged >40 years: data from the national health and nutrition examination survey, 2011–2012. 433021. 2015;130:643–654.
[26] Rymer J, McCoy LA, Thomas L, et al. Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. Am J Cardiol. 2014;114(10):1479–1484.
[27] Shore S, Jones PG, Maddox TM, et al. Longitudinal persistence with secondary prevention therapies relative
to patient risk after myocardial infarction. Heart. 2015;101(10):800–807.

[28] Yasmina A, de Boer A, Deneer VHM, et al. Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period. Br J Clin Pharmacol. 2017;83:632–641.

[29] Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events - a systematic review and meta-analysis. JAMA. 2019;321(3):277–287.

[30] Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.

[31] Juul-Møller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet. 1992;340:1421–1425.

[32] Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Annals of Internal Medicine, 1991, 114, 835-839.

[33] Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.

[34] Arts DL, Abu-Hanna A, Medlock SK, et al. Effectiveness and usage of a decision support system to improve stroke prevention in general practice: A cluster randomized controlled trial. PLoS One. 2017. DOI:10.1371/journal.pone.0170974.

[35] Flodgren G, Goncalves-Bradley DC, Summerbell CD. Interventions to change the behaviour of health professionals and the organisation of care to promote weight reduction in children and adults with overweight or obesity (Review). Cochrane Database Syst Rev. 2017;11:Art. No.: CD000984. DOI:10.1002/14651858.CD000984.pub3

[36] Guiriguet C, Munoz-Ortiz L, Rivero I, et al. Alerts in electronic medical records to promote a colorectal cancer screening programme. Br J Gen Pract. 2016. DOI:10.3399/bjgp16X685657.

[37] Karlsson LO, Nilsson S, Bang M, et al. A clinical decision support tool for improving adherence to guidelines on anticoagulant therapy in patients with atrial fibrillation at risk of stroke: A cluster-randomized trial in a Swedish primary care setting (the CDS-AF study). PLoS Med. 2018. DOI:10.1371/journal.pmed.1002528.

[38] Khalil H, Bell B, Chambers H, et al. Professional, structural and organisational interventions in primary care for reducing medication errors (Review). Cochrane Database Syst Rev. 2017;(10):Art. No.: CD003942. DOI:10.1002/14651858.CD003942.pub3

[39] Konerman MA, Thomson M, Gray K, et al. Impact of an electronic health record alert in primary care on increasing hepatitis C screening and curative treatment for baby boomers. Hepatology. 2017;66(6):1805–1813.

[40] McKibben KA, Lokker C, Handler SM, et al. The effectiveness of integrated health information technologies across the phases of medication management: a systematic review of randomized controlled trials. J Am Med Inform Assoc. 2012;19:22–30.

[41] Dondo TB, Hall M, Timmis AD, et al. Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study. BMJ Open. 2016;6:e011600.

[42] Aboa-Eboulé C, Mengue D, Benzenine E, et al. How accurate is the reporting of stroke in hospital discharge data? A pilot validation study using a population-based stroke registry as control. J Neurol. 2013;260:605–613.

[43] Burkhardt M, Niemaber U, Holstein JH, et al. Trauma registry record linkage: methodological approach to benefit from complementary data using the example of the German pelvic injury register and the traumaRegister DGU®. BMC Med Res Methodol. 2013;13:30–36.

[44] Gurevic Y, McFarlane A, Morris K, et al. Estimating the number of coronary artery bypass graft and percutaneous coronary intervention procedures in Canada: A comparison of cardiac registry and Canadian institute for health information data sources. Can J Cardiol. 2010;26(7):e249–e253.

[45] Hoejemakers F, Beck N, Wouters MWJM, et al. National quality registries: how to improve the quality of data? J Thorac Dis. 2018;10(Suppl 29):S3490–S3499.

[46] Lee SJ, Grobe JE, Tiro JA. Assessing race and ethnicity data quality across cancer registries and EMRs in two hospitals. J Am Med Inform Assoc. 2016;23:627–634.

[47] Seagrave KG, Naylor J, Armstrong E, et al. Data quality audit of the arthroplasty clinical outcomes registry NSW. BMC Health Serv Res. 2014;14:512–517.

[48] Sirirungreung A, Buasom R, Jiraphongs C, et al. Data reliability and coding completeness of cancer registry information using reabstracting method in the national cancer institute: Thailand, 2012 to 2014. J Global Oncol. 2018. DOI:10.1200/JGO.17.00147.

[49] Whedon J, Fulton G, Herr CH, et al. Trauma patients without a trauma diagnosis: the data gap. J Trauma. 2009;67(4):822–828.

[50] Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction- a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J. 2011;32:2376–2386.

[51] Fカラーノ AC, Roe MT. Contemporary reflections on the safety of long-term aspirin treatment for the secondary prevention of cardiovascular disease. Drug Saf. 2016;39 (8):715–727.

[52] Ismail N, Jordan KP, Rao S, et al. Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review. BMJ Open. 2019;9:e023337.